MarketwirePress Release: Theravance, Inc. – Wed, Feb 1, 2012 4:05 PM EST
SOUTH SAN FRANCISCO, CA--(Marketwire -02/01/12)- Theravance, Inc. (NASDAQ: THRX - News) announced today that Rick E Winningham, Chief Executive Officer, is scheduled to present at the following investor conferences in February 2012:
Leerink Swann Global Healthcare Conference
Waldorf Astoria, New York, NY
Thursday, February 16, 2012
9:30 a.m. EST
RBC Capital Markets' Global Healthcare Conference
New York Palace, New York, NY
Tuesday, February 28, 2012
8:30 a.m. EST
Citi Global Healthcare Conference
Waldorf Astoria, New York, NY
Wednesday, February 29, 2012
9:30 a.m. EST
All webcast information will be available on Theravance's web site at www.theravance.com. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
Recent THRX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 02/26/2024 02:00:55 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/16/2024 05:15:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:00:26 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/14/2024 07:26:12 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/14/2024 07:22:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 03:44:05 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:35:19 PM
- Theseus Pharmaceuticals Announces Closing of Tender Offer • PR Newswire (US) • 02/14/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 05:36:57 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 02/07/2024 10:21:30 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 02/07/2024 10:15:51 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 01/30/2024 01:52:31 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 01/30/2024 01:23:43 PM
- Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals • Business Wire • 01/30/2024 01:00:00 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 01/10/2024 02:47:20 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 01/10/2024 01:51:27 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 12/22/2023 11:52:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 11:36:08 AM
- Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right • PR Newswire (US) • 12/22/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 11:30:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 11:37:46 AM
- Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC • PR Newswire (US) • 11/27/2023 11:30:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/24/2023 09:23:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:01:52 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM